Tumor immunotherapy: Mechanisms and clinical applications

被引:11
作者
Nong, Cheng [1 ]
Guan, Pengbo [1 ]
Li, Li [1 ]
Zhang, Huiyuan [1 ]
Hu, Hongbo [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Ctr Immunol & Hematol, Natl Clin Res Ctr Geriatr,State Key Lab Biotherap, Chengdu 610041, Peoples R China
[2] Chongqing Int Inst Immunol, Chongqing, Peoples R China
来源
MEDCOMM-ONCOLOGY | 2022年 / 1卷 / 01期
基金
中国国家自然科学基金;
关键词
CAR-T; immune checkpoint inhibition; immunotherapy; tumor microenvironment; INNATE LYMPHOID-CELLS; REGULATORY T-CELLS; METASTATIC NASOPHARYNGEAL CARCINOMA; PLATINUM-BASED CHEMOTHERAPY; CYTOKINE RELEASE SYNDROME; ACTIVATION GENE-3 LAG-3; NATURAL-KILLER-CELLS; IFN-GAMMA PRODUCTION; STAGE-III MELANOMA; OPEN-LABEL;
D O I
10.1002/mog2.8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy, which aims to enhance the functions of the host's immune system to eliminate invading pathogens and mutant cells, has been widely used for cancer treatment. Despite the enormous progress in immunotherapy, the efficiency of immunotherapy is urgent to be improved. The tumor microenvironment is composed of multiple types of infiltrating immune cells and stromal cells (such as endothelial cells, fibroblasts, and tumor cells), extracellular matrix, various cytokines, chemokines, growth factors, and metabolites, all of which play crucial roles in tumor progress, metastasis, relapse and the outcome of immunotherapy. Emerging evidence indicates a better understanding of the characteristics of the tumor microenvironment and its associated factors, which could lead to uncovering novel promising immunotherapy approaches. This review will summarize the current knowledge of heterogeneity and function of the immune cells in the tumor microenvironment, the current progress of immunotherapy focusing on immune checkpoint blockade and chimeric antigen T cell therapy, as well as the challenge and limitations of the current immunotherapy strategy. Overall, we aim to provide the conceptions of tumor immune microenvironment and application of immunotherapy, highlighting the potential strategies to improve tumor immunotherapy.
引用
收藏
页数:34
相关论文
共 50 条
  • [41] Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
    Lodewijk, Iris
    Nunes, Sandra P.
    Henrique, Rui
    Jeronimo, Carmen
    Duenas, Marta
    Paramio, Jesus M.
    CLINICAL EPIGENETICS, 2021, 13 (01)
  • [42] Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy
    Wang, Ben
    Liu, Mengmeng
    Ran, Zhujie
    Li, Xin
    Li, Jie
    Ou, Yunsheng
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2020, 8
  • [43] Assessing the Future of Solid Tumor Immunotherapy
    Guha, Prajna
    Heatherton, Kara R.
    O'Connell, Kyle P.
    Alexander, Ian S.
    Katz, Steven C.
    BIOMEDICINES, 2022, 10 (03)
  • [44] Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future
    Esin, Ece
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [45] NK cells and ILCs in tumor immunotherapy
    Sivori, Simona
    Pende, Daniela
    Quatrini, Linda
    Pietra, Gabriella
    Della Chiesa, Mariella
    Vacca, Paola
    Tumino, Nicola
    Moretta, Francesca
    Mingari, Maria Cristina
    Locatelli, Franco
    Moretta, Lorenzo
    MOLECULAR ASPECTS OF MEDICINE, 2021, 80
  • [46] Advances in targeting tumor microenvironment for immunotherapy
    Wang, Lugang
    Zhang, Liubo
    Zhang, Zhen
    Wu, Peng
    Zhang, Yi
    Chen, Xinfeng
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [47] Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy
    Bai, Yuzhuo
    Wang, Yun
    Zhang, Xudong
    Fu, Jianhua
    Xing, Xiuli
    Wang, Chunlan
    Gao, Longlan
    Liu, Yu
    Shi, Li
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 570
  • [48] Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
    Pelster, Meredith S.
    Amaria, Rodabe N.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [49] Potential applications of nanoparticles in cancer immunotherapy
    Jia, Yimei
    Omri, Abdelwahab
    Krishnan, Lakshmi
    McCluskie, Michael J.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (01) : 63 - 74
  • [50] Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
    Lisi, Lucia
    Lacal, Pedro Miguel
    Martire, Maria
    Navarra, Pierluigi
    Graziani, Grazia
    PHARMACOLOGICAL RESEARCH, 2022, 175